Kubota Pharmaceutical Holdings and its subsidiary, Kubota Vision Inc., are focused on developing innovative solutions aimed at preserving and restoring vision. Their primary technology, known as Kubota Glass Technology, utilizes a unique active stimulation approach that delivers artificial light stimuli to the retina. This method is designed to inhibit the progression of myopia (nearsightedness) and is already in practical use. The technology is based on the principles of multifocal contact lenses, which have been shown to effectively slow myopia progression by blurring natural light to stimulate the peripheral retina. Kubota's advancements aim to enhance this concept by integrating nanotechnology into eyewear, allowing for direct projection of the most effective images onto the peripheral retina without blurring, thereby achieving a higher efficacy in myopia control with shorter usage times.

In addition to Kubota Glass Technology, the company is developing a range of devices for remote ophthalmic monitoring, including the eyeMO retinal monitoring device and a compact mobile OCT (Optical Coherence Tomography) system. These devices are intended for home use and remote patient monitoring, facilitating better management of eye health. Kubota Pharmaceutical is also advancing low molecular weight compounds for various retinal diseases, including Stargardt disease and proliferative diabetic retinopathy, with ongoing clinical trials to assess their efficacy. Through these technologies and products, Kubota Pharmaceutical is committed to addressing the growing global prevalence of myopia and other vision-related disorders, ultimately striving for a world without blindness.

Japan

Kubota Pharmaceutical Holdings and its subsidiary Kubota　Vision Inc. are committed to translating innovation into a diverse portfolio of drugs and devices to preserve and restore vision for millions of people worldwide.

Kubota Pharmaceutical

Company Details